13P HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): Implications for treatment stratification
Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Esther Carcelero(Hospital Clínic de Barcelona), T. Pascual(Hospital Clínic de Barcelona), C.M. Perou(University of North Carolina at Chapel Hill), E. Seguí Solís(Hospital Clínic de Barcelona), G. Villacampa Javierre(Solti), Jersey Heitor da Silva Maués, A. Prat(Hospital Clínic de Barcelona), P. Villagrasa Gonzalez(Oryzon Genomics (Spain)), Ana Gaspar(University of California, Davis), M. Marin(Oryzon Genomics (Spain)), L. Pare Brunet(Oryzon Genomics (Spain)), J. Soberino García(Hospital Quirónsalud Barcelona), David Romero Romero(Hospital Universitario 12 De Octubre), William Buckingham(Oryzon Genomics (Spain)), Manuel Alva Bianchi(Research Institute Hospital 12 de Octubre), F. Brasó-Maristany(Breast Cancer Research Foundation), P. Tolosa Ortega(Hospital Universitario 12 De Octubre), O. Martínez-Sáez(Hospital Clínic de Barcelona)
Cited by 1
Related Papers
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684